KRRO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Korro Bio Inc (KRRO) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. Despite current technical weakness, strong analyst upgrades, hedge fund buying, and a promising lead program (KRRO-121) with significant upside potential make this a favorable investment opportunity.
The technical indicators show a bearish trend. The MACD is negative and expanding downward, RSI is neutral at 37.269, and moving averages indicate a bearish alignment (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 11.533, with immediate support at 10.779 and resistance at 12.287.
Multiple analyst upgrades with significant price target increases (e.g., Piper Sandler's $30 target and Oppenheimer's $22 target).
Hedge funds are aggressively buying, with a 1445.31% increase in buying activity last quarter.
The lead program KRRO-121 addresses a high unmet need and has strong preclinical data, with analysts bullish on its regulatory path and market potential.
Technical indicators are bearish, suggesting short-term weakness.
Financial performance shows a net income drop of -13.99% YoY and EPS decline of -15.04% YoY in Q3
No recent news or congress trading data to provide additional support.
In Q3 2025, revenue remained flat at $1,090,000 (0.00% YoY), while net income dropped to -$18,061,000 (-13.99% YoY). EPS also declined to -1.92 (-15.04% YoY). However, gross margin remained strong at 100%.
Analysts have overwhelmingly upgraded the stock recently, with firms like Piper Sandler, Oppenheimer, and H.C. Wainwright providing price targets ranging from $15 to $30. Analysts highlight the strong potential of KRRO-121, its differentiated approach, and favorable risk/reward profile.
